- Home
- LAUR vs AKRO Comparison
LAUR vs AKRO Comparison
Compare LAUR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- AKRO
- Stock Information
- Founded
- LAUR 1989
- AKRO 2017
- Country
- LAUR United States
- AKRO United States
- Employees
- LAUR N/A
- AKRO N/A
- Industry
- LAUR Other Consumer Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- AKRO Health Care
- Exchange
- LAUR Nasdaq
- AKRO Nasdaq
- Market Cap
- LAUR 4.3B
- AKRO 4.5B
- IPO Year
- LAUR 2017
- AKRO 2019
- Fundamental
- Price
- LAUR $30.80
- AKRO $54.35
- Analyst Decision
- LAUR Buy
- AKRO Buy
- Analyst Count
- LAUR 3
- AKRO 10
- Target Price
- LAUR $30.67
- AKRO $73.56
- AVG Volume (30 Days)
- LAUR 1.4M
- AKRO 1.4M
- Earning Date
- LAUR 10-30-2025
- AKRO 11-07-2025
- Dividend Yield
- LAUR N/A
- AKRO N/A
- EPS Growth
- LAUR N/A
- AKRO N/A
- EPS
- LAUR 1.36
- AKRO N/A
- Revenue
- LAUR $1,583,936,000.00
- AKRO N/A
- Revenue This Year
- LAUR $8.07
- AKRO N/A
- Revenue Next Year
- LAUR $8.09
- AKRO N/A
- P/E Ratio
- LAUR $22.68
- AKRO N/A
- Revenue Growth
- LAUR 2.01
- AKRO N/A
- 52 Week Low
- LAUR $17.82
- AKRO $21.34
- 52 Week High
- LAUR $32.42
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- LAUR 56.16
- AKRO 67.46
- Support Level
- LAUR $29.49
- AKRO $54.22
- Resistance Level
- LAUR $30.83
- AKRO $54.41
- Average True Range (ATR)
- LAUR 1.33
- AKRO 0.14
- MACD
- LAUR -0.04
- AKRO -0.18
- Stochastic Oscillator
- LAUR 81.58
- AKRO 88.42
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.